News
StockStory.org on MSN16h
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...
Zacks Investment Research on MSN1d
Amgen (AMGN) Stock Moves 1.03%: What You Should KnowAmgen (AMGN) closed the most recent trading day at $280.35, moving +1.03% from the previous trading session. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback